Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Donatsch

Showing results (21-30 of 28) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 28 results.
Biochemical Pharmacology|January 15, 1990
Effect of enzyme induction on Sandimmun (cyclosporin A) biotransformation and hepatotoxicity in cultured rat hepatocytes and in vivoP Bouis, J F Brouillard, V Fischer, et al.
Environmental Mutagenesis|January 1, 1983
Mutagenicity evaluation of amino-oxazoline derivatives using in vitro and in vivo short-term testsW Suter, I Jaeger, R R Racine, et al.
International Journal of Cancer|May 28, 1992
Pharmacologic interactions between the resistance-modifying cyclosporine SDZ PSC 833 and etoposide (VP 16-213) enhance in vivo cytostatic activity and toxicityR P Keller, H J Altermatt, P Donatsch, et al.
Archives of Toxicology|June 1, 1983
Toxicological evaluation of cyclosporin AB Ryffel, P Donatsch, M Madörin, et al.
Hormone and Metabolic Research. Supplement Series|January 1, 1980
Correlations between chanelled Na+ entry, Ca2 + fluxes and insulin release in pancreatic beta-cellsB P Richardson, P Donatsch, R E Hauser, et al.
Toxicology|August 12, 1998
Side effects of brequinar and brequinar analogues, in combination with cyclosporine, in the ratC Pally, D Smith, B Jaffee, et al.
Antimicrobial Agents and Chemotherapy|July 1, 1995
SDZ PRI 053, an orally bioavailable human immunodeficiency virus type 1 proteinase inhibitor containing the 2-aminobenzylstatine moietyA Billich, G Fricker, I Müller, et al.
Antimicrobial Agents and Chemotherapy|August 1, 1994
Inhibition of human immunodeficiency virus type 1 replication by SDZ NIM 811, a nonimmunosuppressive cyclosporine analogB Rosenwirth, A Billich, R Datema, et al.
Pageof 3

Showing results (21-30 of 28) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 28 results.
Biochemical Pharmacology|January 15, 1990
Effect of enzyme induction on Sandimmun (cyclosporin A) biotransformation and hepatotoxicity in cultured rat hepatocytes and in vivoP Bouis, J F Brouillard, V Fischer, et al.
Environmental Mutagenesis|January 1, 1983
Mutagenicity evaluation of amino-oxazoline derivatives using in vitro and in vivo short-term testsW Suter, I Jaeger, R R Racine, et al.
International Journal of Cancer|May 28, 1992
Pharmacologic interactions between the resistance-modifying cyclosporine SDZ PSC 833 and etoposide (VP 16-213) enhance in vivo cytostatic activity and toxicityR P Keller, H J Altermatt, P Donatsch, et al.
Archives of Toxicology|June 1, 1983
Toxicological evaluation of cyclosporin AB Ryffel, P Donatsch, M Madörin, et al.
Hormone and Metabolic Research. Supplement Series|January 1, 1980
Correlations between chanelled Na+ entry, Ca2 + fluxes and insulin release in pancreatic beta-cellsB P Richardson, P Donatsch, R E Hauser, et al.
Toxicology|August 12, 1998
Side effects of brequinar and brequinar analogues, in combination with cyclosporine, in the ratC Pally, D Smith, B Jaffee, et al.
Antimicrobial Agents and Chemotherapy|July 1, 1995
SDZ PRI 053, an orally bioavailable human immunodeficiency virus type 1 proteinase inhibitor containing the 2-aminobenzylstatine moietyA Billich, G Fricker, I Müller, et al.
Antimicrobial Agents and Chemotherapy|August 1, 1994
Inhibition of human immunodeficiency virus type 1 replication by SDZ NIM 811, a nonimmunosuppressive cyclosporine analogB Rosenwirth, A Billich, R Datema, et al.
Pageof 3